Literature DB >> 11883195

Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.

R Galler1, K V Pugachev, C L Santos, S W Ocran, A V Jabor, S G Rodrigues, R S Marchevsky, M S Freire, L F Almeida, A C Cruz, A M Yamamura, I M Rocco, E S da Rosa, L T Souza, P F Vasconcelos, F Guirakhoo, T P Monath.   

Abstract

The yellow fever (YF) 17D virus is one of the most successful vaccines developed to data. Its use has been estimated to be over 400 million doses with an excellent record of safety. In the past 3 years, yellow fever vaccination was intensified in Brazil in response to higher risk of urban outbreaks of the disease. Two fatal adverse events temporally associated with YF vaccination were reported. Both cases had features similar to yellow fever disease, including hepatitis and multiorgan failure. Two different lots of YF 17DD virus vaccine were administered to the affected patients and also to hundreds of thousands of other individuals without any other reported serious adverse events. The lots were prepared from the secondary seed, which has been in continuous use since 1984. Nucleotide sequencing revealed minor variations at some nucleotide positions between the secondary seed lot virus and the virus isolates from patients; these differences were not consistent across the isolates, represented differences in the relative amount of each nucleotide in a heterogeneous position, and did not result in amino acid substitutions. Inoculation of rhesus monkeys with the viruses isolated from the two patients by the intracerebral (ic) or intrahepatic (ih) route caused minimal viremia and no clinical signs of infection or alterations in laboratory markers. Central nervous system histological scores of rhesus monkeys inoculated ic were within the expected range, and there were no histopathological lesions in animals inoculated ih. Altogether, these results demonstrated the genetic stability and attenuated phenotype of the viruses that caused fatal illness in the two patients. Therefore, the fatal adverse events experienced by the vaccinees are related to individual, genetically determined host factors that regulate cellular susceptibility to yellow fever virus. Such increased susceptibility, resulting in clinically overt disease expression, appears to be extremely rare.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11883195     DOI: 10.1006/viro.2001.1168

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Molecular characterization of a hamster viscerotropic strain of yellow fever virus.

Authors:  Monica A McArthur; Miguel T Suderman; John-Paul Mutebi; Shu-Yuan Xiao; Alan D T Barrett
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.

Authors:  Myrna C Bonaldo; Richard C Garratt; Renato S Marchevsky; Evandro S F Coutinho; Alfredo V Jabor; Luís F C Almeida; Anna M Y Yamamura; Adriana S Duarte; Prisciliana J Oliveira; Jackeline O P Lizeu; Luiz A B Camacho; Marcos S Freire; Ricardo Galler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Vaccinating in disease-free regions: a vaccine model with application to yellow fever.

Authors:  Claudia T Codeço; Paula M Luz; Flavio Coelho; Alison P Galvani; Claudio Struchiner
Journal:  J R Soc Interface       Date:  2007-12-22       Impact factor: 4.118

Review 5.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Authors:  Bali Pulendran
Journal:  Nat Rev Immunol       Date:  2009-09-18       Impact factor: 53.106

6.  Statement on Older Travellers: Committee to Advise on Tropical Medicine and Travel.

Authors:  K L McClean
Journal:  Can Commun Dis Rep       Date:  2011-07-21

Review 7.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

8.  CD8+ T cells complement antibodies in protecting against yellow fever virus.

Authors:  Maria R Bassi; Michael Kongsgaard; Maria A Steffensen; Christina Fenger; Michael Rasmussen; Karsten Skjødt; Bente Finsen; Anette Stryhn; Søren Buus; Jan P Christensen; Allan R Thomsen
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

9.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.